Details of the Drug

General Information of Drug (ID: DMNSJFD)

Drug Name

INDORAMIN

Synonyms

INDORAMIN; Indoramine; 26844-12-2; Indoramina; Wy-21901; Indoraminum [INN-Latin]; Indoramine [INN-French]; Indoramina [INN-Spanish]; UNII-0Z802HMY7H; Baratol; EINECS 248-041-5; BRN 0494035; WY 21901; 0Z802HMY7H; CHEMBL279516; C22H25N3O; Benzamide, N-(1-(2-(1H-indol-3-yl)ethyl)-4-piperidinyl)-; 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole; JXZZEXZZKAWDSP-UHFFFAOYSA-N; N-(1-(2-Indol-3-ylethyl)-4-piperidyl)benzamide; N-(1-(2-(1H-Indol-3-yl)ethyl)-4-piperidinyl)benzamide; Benzamide, N-(1-(2-indol-3-ylethyl)-4-piperidyl)-; Benzamide, N

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Withdrawn from market	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

347.5

Logarithm of the Partition Coefficient (xlogp)

4.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [3]
Elimination: 5% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.3 hours [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.223 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.15% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.9 L/kg [3]

Chemical Identifiers

Formula: C22H25N3O
IUPAC Name: N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide
Canonical SMILES: C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43
InChI: InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
InChIKey: JXZZEXZZKAWDSP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 33625
ChEBI ID: CHEBI:135470
CAS Number: 26844-12-2
DrugBank ID: DB08950
TTD ID: D02LHR
INTEDE ID: DR0876

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Inhibitor	[5]
Adrenergic receptor alpha-2B (ADRA2B)	TTWM4TY	ADA2B_HUMAN	Inhibitor	[5]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1A adrenergic receptor (ADRA1A)	OTUIWCL5	ADA1A_HUMAN	Protein Interaction/Cellular Processes	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Hypertension

ICD Disease Classification

BA00-BA04

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor alpha-2C (ADRA2C)	DTT	ADRA2C	1.76E-01	-0.06	-0.28
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 501).
2	BDDCS applied to over 900 drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
6	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
7	Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995 Jan 16;288(2):201-7. doi: 10.1016/0922-4106(95)90195-7.